CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer
- 31 December 2010
- journal article
- research article
- Published by Elsevier BV in Clinical Breast Cancer
- Vol. 10 (6), 489-491
- https://doi.org/10.3816/cbc.2010.n.065
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Novel anticancer targets: revisiting ERBB2 and discovering ERBB3Nature Reviews Cancer, 2009
- Locally recurrent or metastatic breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-upAnnals of Oncology, 2008
- Two Concurrent Phase II Trials of Paclitaxel/Carboplatin/Trastuzumab (Weekly or Every-3-Week Schedule) as First-Line Therapy in Women with HER2-Overexpressing Metastatic Breast Cancer: NCCTG Study 983252Clinical Breast Cancer, 2005
- Extending Survival with Chemotherapy in Metastatic Breast CancerThe Oncologist, 2005
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- HER-2 Testing in Breast Cancer Using Parallel Tissue-Based MethodsJAMA, 2004
- HER2 Amplification Ratios by Fluorescence In Situ Hybridization and Correlation with Immunohistochemistry in a Cohort of 6556 Breast Cancer TissuesClinical Breast Cancer, 2004
- NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancerThe EMBO Journal, 2000
- A Hierarchical Network of Interreceptor Interactions Determines Signal Transduction by Neu Differentiation Factor/Neuregulin and Epidermal Growth FactorMolecular and Cellular Biology, 1996
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987